STERIS (STE) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

STE Stock Forecast


STERIS stock forecast is as follows: an average price target of $262.50 (represents a 26.51% upside from STE’s last price of $207.49) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

STE Price Target


The average price target for STERIS (STE) is $262.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $265.00 to $260.00. This represents a potential 26.51% upside from STE's last price of $207.49.

STE Analyst Ratings


Buy

According to 4 Wall Street analysts, STERIS's rating consensus is 'Buy'. The analyst rating breakdown for STE stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

STERIS Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Jason BednarPiper Sandler$260.00$221.1517.57%25.31%
Sep 03, 2024Brett FishbinKeyBanc$265.00$241.109.91%27.72%
May 10, 2024Jason BednarPiper Sandler$225.00$225.94-0.42%8.44%
Apr 04, 2024Mike PolarkWolfe Research$245.00$216.6513.09%18.08%

The latest STERIS stock forecast, released on Oct 24, 2024 by Jason Bednar from Piper Sandler, set a price target of $260.00, which represents a 17.57% increase from the stock price at the time of the forecast ($221.15), and a 25.31% increase from STE last price ($207.49).

STERIS Price Target by Period


1M3M12M
# Anlaysts-14
Avg Price Target-$260.00$248.75
Last Closing Price$207.49$207.49$207.49
Upside/Downside-100.00%25.31%19.89%

In the current month, the average price target of STERIS stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to STERIS's last price of $207.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024StephensMarket OutperformMarket OutperformHold
Oct 24, 2024Piper SandlerUnderperformUnderperformHold
Oct 24, 2024Piper SandlerNeutralOverweightUpgrade
Sep 03, 2024StephensMarket OutperformMarket OutperformHold
Sep 03, 2024JMP SecuritiesUnderperformUnderperformHold
Sep 03, 2024KeyBancOverweightOverweightHold
Aug 07, 2024StephensMarket OutperformMarket OutperformHold
Jun 10, 2024Piper SandlerNeutralNeutralHold
May 10, 2024Piper SandlerNeutralNeutralHold
Apr 04, 2024Wolfe ResearchOutperformOutperformHold
Feb 09, 2024StephensMarket OutperformMarket OutperformHold
Aug 03, 2023Morgan StanleyEqual-WeightEqual-WeightHold

STERIS's last stock rating was published by Stephens on Oct 24, 2024. The company gave STE a "Market Outperform" rating, the same as its previous rate.

STERIS Financial Forecast


STERIS Revenue Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Revenue-------------$1.40B$1.34B$1.28B$1.38B$1.22B$1.20B$1.16B$1.21B$968.42M$1.20B$1.21B$873.53M$668.93M$756.13M$808.92M$822.99M$696.80M
Avg Forecast$1.69B$1.56B$1.51B$1.44B$1.58B$1.47B$1.41B$1.36B$1.50B$1.38B$1.33B$1.27B$1.41B$1.35B$1.30B$1.21B$1.27B$1.27B$1.22B$1.22B$1.17B$1.19B$1.15B$904.86M$876.22M$793.03M$719.54M$643.38M$799.57M$748.45M
High Forecast$1.70B$1.57B$1.52B$1.45B$1.60B$1.48B$1.43B$1.38B$1.51B$1.39B$1.33B$1.27B$1.41B$1.36B$1.31B$1.22B$1.28B$1.28B$1.22B$1.22B$1.17B$1.19B$1.15B$904.86M$876.22M$793.03M$719.54M$643.38M$799.57M$748.45M
Low Forecast$1.67B$1.54B$1.49B$1.42B$1.56B$1.45B$1.40B$1.35B$1.48B$1.37B$1.33B$1.27B$1.41B$1.34B$1.28B$1.19B$1.26B$1.26B$1.22B$1.22B$1.17B$1.19B$1.15B$904.86M$876.22M$793.03M$719.54M$643.38M$799.57M$748.45M
# Analysts4444433355411354433334444415998
Surprise %-------------1.03%1.03%1.06%1.09%0.96%0.98%0.95%1.03%0.81%1.04%1.34%1.00%0.84%1.05%1.26%1.03%0.93%

STERIS's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.41B, with a low forecast of $1.41B, and a high forecast of $1.41B. STE's average Quarter revenue forecast represents a 1.13% increase compared to the company's last Quarter revenue of $1.40B (Dec 23).

STERIS EBITDA Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts4444433355411354433334444415998
EBITDA-------------$216.16M$185.86M$188.92M$226.12M$190.88M$318.09M$158.45M$91.92M$76.47M$230.90M$322.78M$203.66M$165.41M$196.79M$205.17M$208.54M$158.58M
Avg Forecast$424.04M$392.39M$379.00M$362.05M$397.78M$369.37M$355.38M$342.81M$377.01M$347.58M$334.60M$320.02M$344.19M$339.16M$326.75M$303.66M$312.90M$527.34M$240.36M$240.60M$284.45M$234.89M$226.54M$177.97M$224.86M$155.98M$141.52M$126.54M$200.70M$147.21M
High Forecast$427.93M$395.98M$382.47M$365.36M$401.43M$372.75M$358.64M$345.95M$379.52M$350.10M$334.62M$320.02M$413.03M$341.69M$330.36M$306.44M$375.48M$632.80M$240.36M$240.60M$341.34M$234.89M$226.54M$177.97M$269.84M$155.98M$141.52M$126.54M$240.85M$147.21M
Low Forecast$419.10M$387.82M$374.59M$357.83M$393.15M$365.06M$351.24M$338.81M$371.98M$345.06M$334.57M$320.02M$275.35M$336.63M$322.57M$300.12M$250.32M$421.87M$240.36M$240.60M$227.56M$234.89M$226.54M$177.97M$179.89M$155.98M$141.52M$126.54M$160.56M$147.21M
Surprise %-------------0.64%0.57%0.62%0.72%0.36%1.32%0.66%0.32%0.33%1.02%1.81%0.91%1.06%1.39%1.62%1.04%1.08%

1 analysts predict STE's average Quarter EBITDA for Mar 24 to be $344.19M, with a high of $413.03M and a low of $275.35M. This is 59.23% upper than STERIS's previous annual EBITDA (Dec 23) of $216.16M.

STERIS Net Income Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts4444433355411354433334444415998
Net Income-------------$140.74M$115.32M$123.55M$187.22M$123.83M$-315.23M$111.26M$52.26M$-21.90M$69.81M$-21.81M$88.85M$88.12M$105.86M$88.19M$123.32M$104.93M
Avg Forecast$311.79M$277.96M$262.73M$244.01M$283.89M$252.47M$235.61M$226.52M$260.48M$230.44M$210.60M$196.14M$147.46M$215.13M$198.74M$184.52M$134.05M$144.21M$197.10M$190.31M$121.87M$194.98M$180.86M$148.27M$96.34M$150.89M$125.88M$97.19M$118.63M$141.11M
High Forecast$315.50M$281.28M$265.86M$246.91M$287.27M$255.48M$238.42M$229.21M$261.48M$235.42M$211.15M$196.15M$176.95M$217.12M$204.67M$186.72M$160.87M$173.05M$197.10M$190.31M$146.24M$198.48M$180.86M$148.27M$115.61M$150.89M$125.88M$97.19M$142.36M$141.11M
Low Forecast$307.07M$273.75M$258.75M$240.31M$279.59M$248.65M$232.04M$223.08M$259.48M$228.44M$210.04M$196.13M$117.97M$214.13M$187.86M$181.72M$107.24M$115.37M$197.10M$190.31M$97.49M$191.47M$180.86M$148.27M$77.07M$150.89M$125.88M$97.19M$94.91M$141.11M
Surprise %-------------0.65%0.58%0.67%1.40%0.86%-1.60%0.58%0.43%-0.11%0.39%-0.15%0.92%0.58%0.84%0.91%1.04%0.74%

STERIS's average Quarter net income forecast for Mar 24 is $147.46M, with a range of $117.97M to $176.95M. STE's average Quarter net income forecast represents a 4.77% increase compared to the company's last Quarter net income of $140.74M (Dec 23).

STERIS SG&A Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts4444433355411354433334444415998
SG&A-------------$360.52M$380.65M$359.06M$335.91M$305.14M$323.19M$334.63M$453.64M$393.75M$344.80M$310.56M$221.07M$155.17M$172.71M$182.37M$189.06M$178.78M
Avg Forecast$440.16M$407.30M$393.41M$375.81M$412.91M$383.41M$368.89M$355.84M$391.34M$360.79M$347.31M$332.18M$366.90M$352.05M$339.17M$315.21M$333.54M$311.84M$317.71M$318.04M$303.22M$310.48M$299.44M$235.25M$239.70M$206.18M$187.07M$167.27M$181.88M$194.58M
High Forecast$444.19M$411.04M$397.01M$379.25M$416.69M$386.92M$372.27M$359.10M$393.95M$363.40M$347.34M$332.18M$440.28M$354.68M$342.92M$318.09M$400.25M$374.21M$317.71M$318.04M$363.86M$310.48M$299.44M$235.25M$287.64M$206.18M$187.07M$167.27M$218.26M$194.58M
Low Forecast$435.03M$402.56M$388.82M$371.43M$408.09M$378.94M$364.59M$351.69M$386.12M$358.18M$347.29M$332.18M$293.52M$349.42M$334.83M$311.53M$266.83M$249.47M$317.71M$318.04M$242.58M$310.48M$299.44M$235.25M$191.76M$206.18M$187.07M$167.27M$145.51M$194.58M
Surprise %-------------1.02%1.12%1.14%1.01%0.98%1.02%1.05%1.50%1.27%1.15%1.32%0.92%0.75%0.92%1.09%1.04%0.92%

STERIS's average Quarter SG&A projection for Mar 24 is $366.90M, based on 1 Wall Street analysts, with a range of $293.52M to $440.28M. The forecast indicates a 1.77% rise compared to STE last annual SG&A of $360.52M (Dec 23).

STERIS EPS Forecast

Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
# Analysts4444433355411354433334444415998
EPS-------------$1.42$1.17$1.25$1.89$1.24$-3.15$1.11$0.52$-0.24$0.70$1.43$1.02$1.04$1.24$1.34$1.45$1.00
Avg Forecast$3.14$2.80$2.65$2.46$2.86$2.54$2.38$2.28$2.63$2.32$2.12$1.98$2.35$2.17$2.00$1.86$2.15$2.19$1.98$1.92$2.02$1.96$1.82$1.49$1.77$1.52$1.27$0.98$1.57$1.42
High Forecast$3.18$2.84$2.68$2.49$2.90$2.58$2.40$2.31$2.64$2.37$2.13$1.98$2.38$2.19$2.06$1.88$2.17$2.22$1.98$1.92$2.02$2.00$1.82$1.49$1.77$1.52$1.27$0.98$1.57$1.42
Low Forecast$3.10$2.76$2.61$2.42$2.82$2.51$2.34$2.25$2.62$2.30$2.12$1.98$2.31$2.16$1.89$1.83$2.12$2.16$1.98$1.92$2.02$1.93$1.82$1.49$1.77$1.52$1.27$0.98$1.57$1.42
Surprise %-------------0.65%0.58%0.67%0.88%0.57%-1.59%0.58%0.26%-0.12%0.38%0.96%0.57%0.68%0.98%1.37%0.92%0.70%

According to 1 Wall Street analysts, STERIS's projected average Quarter EPS for Mar 24 is $2.35, with a low estimate of $2.31 and a high estimate of $2.38. This represents a 65.49% increase compared to STE previous annual EPS of $1.42 (Dec 23).

STERIS Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LIVNLivaNova$49.94$68.2536.66%Buy
BRKRBruker$57.81$79.0036.65%Buy
CNMDCONMED$71.23$97.0036.18%Buy
OFIXOrthofix Medical$17.93$24.0033.85%
STESTERIS$209.51$262.5025.29%Buy
IRTCiRhythm$91.45$111.3821.79%Buy
ITGRInteger$136.68$153.5012.31%Buy
SYKStryker$370.81$408.3310.12%Buy
SNNSmith & Nephew$25.44$27.006.13%Buy
ZIMVZimVie$13.95$14.503.94%Buy
PODDInsulet$263.35$268.001.77%Buy
GKOSGlaukos$146.35$144.14-1.51%Buy
MASIMasimo$174.07$168.33-3.30%Buy
PENPenumbra$247.55$230.25-6.99%Buy

STE Forecast FAQ


Is STERIS a good buy?

Yes, according to 4 Wall Street analysts, STERIS (STE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of STE's total ratings.

What is STE's price target?

STERIS (STE) average price target is $262.5 with a range of $260 to $265, implying a 26.51% from its last price of $207.49. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will STERIS stock go up soon?

According to Wall Street analysts' prediction for STE stock, the company can go up by 26.51% (from the last price of $207.49 to the average price target of $262.5), up by 27.72% based on the highest stock price target, and up by 25.31% based on the lowest stock price target.

Can STERIS stock reach $300?

STE's average twelve months analyst stock price target of $262.5 does not support the claim that STERIS can reach $300 in the near future.

What are STERIS's analysts' financial forecasts?

STERIS's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $5.83B (high $5.88B, low $5.76B), average EBITDA is $1.47B (high $1.48B, low $1.45B), average net income is $998.49M (high $1.01B, low $983.37M), average SG&A $1.52B (high $1.53B, low $1.5B), and average EPS is $10.06 (high $10.18, low $9.91). STE's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $6.19B (high $6.25B, low $6.12B), average EBITDA is $1.56B (high $1.57B, low $1.54B), average net income is $1.1B (high $1.11B, low $1.08B), average SG&A $1.62B (high $1.63B, low $1.6B), and average EPS is $11.05 (high $11.18, low $10.89).

Did the STE's actual financial results beat the analysts' financial forecasts?

Based on STERIS's last annual report (Mar 2023), the company's revenue was $4.96B, which missed the average analysts forecast of $4.99B by -0.66%. Apple's EBITDA was $1.25B, missing the average prediction of $1.32B by -5.37%. The company's net income was $107.03M, missing the average estimation of $665.67M by -83.92%. Apple's SG&A was $1.3B, beating the average forecast of $1.28B by 1.39%. Lastly, the company's EPS was $1.07, missing the average prediction of $8.24 by -87.01%. In terms of the last quarterly report (Dec 2023), STERIS's revenue was $1.4B, beating the average analysts' forecast of $1.35B by 3.49%. The company's EBITDA was $216.16M, missing the average prediction of $339.16M by -36.27%. STERIS's net income was $140.74M, missing the average estimation of $215.13M by -34.58%. The company's SG&A was $360.52M, beating the average forecast of $352.05M by 2.41%. Lastly, the company's EPS was $1.42, missing the average prediction of $2.17 by -34.52%